Trial Profile
A single-arm, single-center, open-label clinical study of apatinib in the treatment of metastatic renal cell carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Apr 2018 New trial record